opment during the follow-up period. 20 On the contrary, they found that lesions < 2 cm in size and growing less than 10% per year have a 0% chance of symptom development. Gamma Knife surgery would seemingly be an ideal preemptive treatment for high-risk lesions given the procedure's low morbidity and excellent tumor control and PFS rates for benign meningiomas, which typically exceed 90% at 5 years. 1, 17 However, because the primary goal of preemptive treatment is to avoid symptom development altogether, the traditional outcome measures for tumor control and PFS can be difficult to interpret in the setting of a disease that under certain circumstances has excellent PFS if left untreated. The primary aim in the present study was to further examine the role of GKS as a treatment for asymptomatic meningiomas with an emphasis on symptom control, treatment complications, and a novel method of comparison with published natural history studies documenting rates of symptom development that are more applicable to asymptomatic patients.
Methods

Study Design and Patient Selection
This retrospective analysis was performed with patients from a prospectively maintained institutional review board-approved database that included all patients treated with GKS at the University of Virginia. The database was screened for patients meeting our inclusion and exclusion criteria. Patients were required to have neuroimaging findings consistent with a diagnosis of meningioma. Findings on MRI and CT that were consistent with a meningioma included a dura-based, extraaxial location; partial calcification; and postcontrast enhancement. Patients with a recent history of metastatic cancer were excluded from the study.
Most lesions were diagnosed with MRI; however, CT studies were acceptable if MRI had been contraindicated. Patients were required to be asymptomatic at the time of treatment. If the patient had previously undergone a resection, he or she was required to be asymptomatic before that resection as well. Patients who experienced seizures, paresis, sensory disturbances, aphasia, cranial nerve deficits, hydrocephalus, or visual disturbances were excluded. Some nonspecific symptoms did not preclude participation in the study-headaches, nausea, dizziness, memory deficits, or weight loss-unless they localized to the side/site of the tumor and appeared to be connected to the meningioma (for example, a skull base meningioma compressing the acoustic nerve with accompanying dizziness). Additionally, exceptions were made for neurological deficits directly linked to morbidity from a previous tumor resection. Patients with WHO Grade II or III pathology were also excluded. A minimum of 12 months of imaging and clinical follow-up was required for inclusion in the study.
Radiosurgical Technique
Stereotactic radiosurgery was performed in the same manner previously described for the University of Virginia. 19 In the operating room, with the patient under anesthesia (monitored by anesthesiologist), a stereotactic Leksell G frame is placed on the cranium. Stereotactic MRI is performed as thin-slice (1 mm), axial and coronal, T1-weighted pre-and postcontrast MR sequences. A collaborative treatment plan is formulated in consultation among the treating neurosurgeon, medical physicist, and radiation oncologist. The Leksell Gamma Unit Model U was used until July 2001 and then was replaced by Model C (Elekta Instruments, Inc.). Kula software was used for dose planning from 1989 until June 1994 and then was replaced with Elekta's GammaPlan software. The date of GKS was defined as the date of initial treatment in these patients.
Data Collection and Follow-Up
From the patient's medical records and the Gamma Knife database, demographic information was collected: age, sex, symptom status, duration from diagnosis to treatment, prior resections, prior XBRT, pathology, and lesion location. Special emphasis was placed on obtaining the reason the patient underwent GKS. Reasons were divided into 4 categories: patient preference, residual tumor, recurrent tumor, or documented tumor growth. Patient preference includes those patients who, upon learning that they had a meningioma, decided to forgo the conservative management route and sought immediate treatment. Frequently, these patients were referred for GKS because they had lesions that would have been challenging to surgically resect. The residual tumor group was treated with GKS shortly after undergoing resection when residual lesion was found postoperatively. The recurrent tumor group includes patients who had previously undergone complete resection and were found to have a recurrent lesion at a later date. The group with documented tumor growth includes patients who initially chose conservative management but on follow-up scans showed signs of tumor growth. This group also includes patients who had a known residual lesion that was conservatively monitored and then displayed growth. Lastly, radiosurgical parameters were collected from the patient's operative notes, including peripheral dose, maximum dose, tumor volumes, and number of isocenters used. The isodose percentage was calculated as the ratio of the peripheral to maximum doses.
Imaging follow-up occurred every 6 months for 1 year and annually thereafter. Follow-up imaging was performed at specifications similar to those used for the original stereotactic MRI, that is, thin-slice T1-weighted images preand post-Gd enhancement. Additionally, a T2 series was added to aid in identifying radiation injury. The treating neurosurgeon along with a neuroradiologist reviewed all follow-up neuroimaging studies, which were analyzed for tumor growth. When imaging studies were available, tumors were classified as stable if they were within ± 15% of the original tumor volume. This margin accounts for inherent uncertainties in the imaging technique and measurement variability. Tumors were classified as decreased if the volume change was less than 15% of the original volume or increased if they were greater than 15% of the original volume. Tumor control was defined as either a stable or decreased lesion. All follow-up scans were screened for signs of radiation-induced parenchymal injury. Lastly, the development of any new lesion not previously treated with GKS was documented. Tumor calcification was not assessed in this study because the majority of patients underwent MRI, as opposed to CT scanning, the preferred modality for detecting calcification.
Preferably, clinical follow-up was performed by the treating neurosurgeon at the University of Virginia at 6-to 12-month intervals. However, because of the wide geographic referral base, clinical follow-up was also acceptable if performed by the referring physician on a schedule of his or her choosing. If clinical follow-up information was not available, the patient was contacted, and University of Virginia clinical team members assessed whether any symptoms had developed since the time of GKS. Otherwise, follow-up included a full neurological examination for new deficits. Additionally, any subsequent treatments beyond GKS were documented. Lastly, the Social Security Death Index was screened for the date of death of any deceased patients. The overall survival of these patients was calculated based on the date of GKS to the date of death regardless of the cause of death.
Statistical Analysis
Statistical analyses were performed using the IBM SPSS 20 statistical software (IBM SPSS, Inc.) and Microsoft Excel (Microsoft, Inc.). Actuarial tumor control, symptom control, and overall PFS were determined using a Kaplan-Meier method. For symptom control, the development of symptoms was the only factor analyzed.
In the overall PFS analysis, an event was defined as tumor growth, symptom development, death, or treatment complication.
Results
Patient Demographics and Treatment Characteristics
An initial cohort of 923 patients with meningiomas was narrowed to 67 patients with asymptomatic meningiomas. When the remaining criteria were applied, 42 patients were eligible for analysis. Among these patients were 33 females (78.6%) and 9 males (21.4%). Patients were treated over a 14-year period from April 5, 1994 , to December 4, 2007. The median age at the time of treatment was 53 years, with a range from 21 to 86 years. Two patients (4.8%) had a cranial nerve palsy attributed to a previous resection. Only 1 patient (2.4%) had a hearing deficit due to a vestibular schwannoma. During this patient's previous GKS for the vestibular schwannoma, a meningioma was diagnosed and subsequently monitored until GKS treatment of the meningioma was performed. Eighteen (42.9%) of the 42 patients claimed to experience headaches prior to treatment or had a headache that prompted neuroimaging. The remaining patients underwent imaging as a result of unrelated issues such as posttrauma, nonspecific complaints, and so forth. Otherwise, patients had no neurological symptoms. Reasons for treatment were categorized as follows: patient preference, 17 (40.5%); documented tumor growth on serial neuroimaging studies, 11 (26.2%); recurrent lesion, 5 (11.9%); and residual lesion, 9 (21.4%). Nineteen patients (45.2%) had undergone a resection prior to GKS for the meningioma. One patient (2.4%) had undergone prior XBRT, and 1 (2.4%) had had a previous LINAC treatment. Forty-two lesions were treated, and the lesion location varied widely. The most common location was the cerebral convexities (10 lesions [23.8%]), followed by the falcine/ parasagittal region (8 lesions [19%] ). Other locations were as follows: cavernous sinus, 7 (16.7%); petroclival region, 6 (14.3%); parasellar region, 3 (7.1%); clinoid region, 3 (7.1%); and tentorium, planum sphenoidale, jugular foramen, and cribriform plate, 1 each (2.4%). Table 1 summarizes patient demographics, previous treatments, reasons for treatment, and lesion locations.
Radiosurgically, the median tumor volume of treated lesions was 4.0 ml (range 0.23-17.0 ml). Maximum lesion dimensions were as follows: < 2 cm, 10 (23.8%); 2-2.5 cm, 7 (16.7%); > 2.5 cm, 18 (42.8%); and unknown, 7 (16.7%). The median tumor margin or peripheral dose was 15 Gy (10-18 Gy), and the median maximal radiation dose was 31.6 Gy (20-50 Gy). The median prescribed isodose was 48% (30%-55%). The median number of isocenters was 6 (range 1-27). Table 2 summarizes radiosurgical treatment parameters.
Imaging Results
The median duration of the imaging follow-up was Fig. 1A , and a summary of results is presented in Table 3 . An additional meningioma developed in 2 patients (4.8%) during the follow-up period but was treated in neither patient. A single patient (2.4%) demonstrated minimally increased T2 signal hyperintensity in the brain parenchyma adjacent to the treatment site. This possible evidence of radiation-induced parenchymal injury in the form of minimal T2 hyperintensity was demonstrated 67 months post-GKS. The hyperintensity was not present at the time of radiosurgery. This patient had not undergone a previous resection; therefore, the changes could not be attributed to postoperative gliosis. Clinical follow-up for this patient continued 36 months beyond the last scan, and the patient remained asymptomatic. No steroids were initiated in this patient.
No evidence of radiation-induced neoplasia or radiation-induced tumor transformation was seen on follow-up neuroimaging studies.
Clinical Results
The median clinical follow-up duration was 76 months, with a range of 12-162 months. A clinical follow-up duration > 36 months was achieved for 35 patients (83%). Two (4.8%) of the 42 patients demonstrated symptoms during the follow-up period. One patient with a tumor located in the left parasagittal region just anterior to the precentral gyrus experienced progressive, right-sided paresis 41 months post-GKS. The paresis developed over several days. The tumor was stable in size, and the last MRI study had been performed 3 weeks prior to the appearance of symptoms. Additionally, no signal abnormalities were present to suggest edema. The other patient with symptoms harbored a right clival lesion that extended across the midline. She experienced left-sided neuralgia and hypesthesia in the V1 and V2 distributions beginning 66 months after GKS. Magnetic resonance imaging at the time of symptom appearance and 36 months later showed a stable lesion. Again, no signal abnormalities consistent with edema were present on any images. Actuarial symptom control at 5 and 10 years was 97% and 93.1%, respectively. Through the Social Security Death Index, we found 4 patients who were deceased with a median overall survival of 135.6 months. Therefore, overall PFS was 91.1% and 77.8% at 5 and 10 years, respectively. The decrease in PFS toward the end of the follow-up period was attributable to the several patients who died and the low number of patients still included in the analysis at that point. Kaplan-Meier curves of symptom control and overall PFS are presented in Fig. 1B and C. A summary of the clinical follow-up is also presented in Table 3 .
In patients with nonspecific headaches prior to GKS (18 patients), clinical follow-up pertaining to those headaches was available in 13 (72.2%). At the last follow-up, 5 patients' (38.5%) headaches were unchanged in quality and intensity. Seven patients (53.8%) claimed improved headaches, whereas 1 patient (7.7%) claimed the headaches were worse than preoperatively. This latter patient claimed that the headaches were migraines and that she was under the care of a neurologist. This patient's tumor was unchanged in size from the time of GKS.
Additional Treatments After GKS
The patient with the only uncontrolled tumor underwent an additional GKS procedure 56 months after the original treatment. That patient was subsequently lost to follow-up, and no additional information beyond the second treatment was available. At the time of the second treatment, the patient remained asymptomatic despite demonstrating an increase in the size of the lesion. No other patients underwent further treatment.
Discussion
From published studies focusing on GKS as a treatment for benign meningiomas, it is clear that the procedure affords excellent tumor control and PFS, with rates typically exceeding 90% at 5 years. 1 The tumor control rate in our series of asymptomatic patients is consistent with these results, with a 5-year actuarial value of 95.7%. Additionally, the overall PFS rate was 91.1% at 5 years. Finally, 54.8% of the lesions decreased in size. Because meningiomas very rarely shrink without intervention, this is strong evidence that GKS may significantly alter normal tumor growth patterns.
While these data may seem promising, there are combinations of factors for which the natural history of an untreated lesion would also demonstrate PFS rates > 90%. 20 Given the primary consideration of maintaining an asymptomatic patient's symptom-free status, solely analyzing tumor control and PFS rates without considering the lesion's natural history may not provide enough information to draw definitive conclusions on whether prophylactic GKS treatment of an asymptomatic patient is beneficial. Two pieces of information are required of the medical literature to answer this question: What lesions are most likely to cause symptoms, and does the rate of symptom development decrease when the tumor is treated with GKS? If surgeons are to treat asymptomatic patients, the treatment must offer minimal morbidity and afford a reasonably high chance of maintaining the patient's asymptomatic status. More information is available regarding the first question than the second. A recent, systematic review of 22 papers covering the natural history of untreated meningiomas illustrates the challenge of identifying which patients should be treated and which should be managed conservatively. 20 Sughrue and colleagues 20 identified differences in symptom development and disease progression based on lesion location, initial lesion size, neuroimaging characteristics, and lesion growth pattern. For instance, 61% of patients with cavernous sinus lesions later demonstrated new or progressive symptoms during a median follow-up of 4.6 years. However, only 5% of patients with sphenoid wing lesions experienced new or progressive symptoms. Obviously, the former group may benefit from early treatment more so than the latter. Lesions in other areas-28% petroclival and 40% cerebellopontine angle-were also associated with symptom development. Sughrue and colleagues 20 also found that specific patterns of lesion growth and size were more likely to cause symptoms. For instance, lesions 2-2.5 cm in size and growing more than 10% per year had a 42.3% rate of symptom development. Compare these lesions with those smaller than 2 cm in size with less than 10% annual growth, 0% of which caused symptoms. Given the multitude of variables contributing to the disease process, determining whether an asymptomatic individual should be exposed to the risks of radiosurgery to prevent disease-related morbidity is challenging. Uncertainty is inherently associated with predictions at the level of a single patient's future neurological state from a meningioma.
There is a paucity of literature on the second question of whether stereotactic radiosurgery will alter the development of symptoms in asymptomatic patients. This may be partly explained by the lack of separation between symptom development and tumor progression when analyzing PFS. For instance, Jo et al. 9 compared the PFS of 77 conservatively treated asymptomatic patients with that of 69 patients initially treated with GKS. At 5 years, PFS for the conservatively treated group was 61.8%, while it was 100% for the GKS-treated group. The difference between these groups was statistically significant. However, it is unclear what proportion had disease progression due to tumor growth and what proportion due to symptom development, as it is expected that some percentage of untreated lesions will increase in size. Symptom development is probably more relevant to the patient's quality of life.
For this reason, we present what we believe is a unique focus on asymptomatic patients and subsequent symptom development. In our series, 2 (4.8%) of 42 patients demonstrated permanent neurological deficits clearly related to their lesions. Table 4 compares symptom control in the present study with that in the untreated patients described in the Sughrue et al. analysis. 20 Across all lesion locations, our patients demonstrate rates of symptom control that are superior to those in the untreated patients. While it is difficult to determine whether these differences are statistically significant for the groups with low patient numbers, these results are promising for GKS's ability to alter the natural history of these asymptomatic lesions. In particular, the results appear especially promising for patients with cavernous sinus lesions. In our study, none of the 7 patients with cavernous sinus lesions later demonstrated symptoms. Compare this with the lesion's natural history, in which 61% of patients became symptomatic. 20 Cavernous sinus lesions have tended to have more prophylactic treatments. 8 We can also compare the rate of symptom development based on lesion size. In our series, both patients who became symptomatic harbored tumors larger than 2.5 cm, resulting in an 11% rate of symptom development in the 18 patients with lesions larger than 2.5 cm. In comparing this finding with data in the Sugrhue et al. analysis, we find a 17.1% rate for lesions of the same size growing less than 10% annually. 20 Their rate for lesions growing more than 10% was unknown because of insufficient data, but it can logically be assumed to be higher. 20 We lack adequate pre-GKS imaging to determine the preoperative growth rate in our series. Nonetheless, our rate of symptom development in this group appears to be lower.
A treatment option with minimal morbidity is paramount in asymptomatic patients. Gamma Knife surgery has historically offered low morbidity and complications compared with those for microsurgery. 17 In a study of asymptomatic patients, Jo et al. 9 attributed no permanent deficits to GKS but did find that minor complications, such as headaches, alopecia, dizziness, and transient focal deficits, occurred in 39.1% of patients. Importantly, only 3 patients (4.8%) required treatment with steroids for more than 2 weeks to decrease edema. In our study, we had no instances of acute radiation toxicity. However, our followup may not have been detailed enough to capture the minor complications such as transient headaches associated with stereotactic frame placement or removal. A single patient (2.4%) demonstrated very mild T2 hyperintensity adjacent to the treatment site, possibly indicating radiation-induced injury. This patient remained asymptomatic, and the imaging findings were of no clinical significance.
Our study has several limitations. First, it is a retrospective chart review and therefore subject to the limitations inherent to this study design. Most importantly, our patient number is limited, and there were no casematched controls. Because of the small number of complications and uncontrolled tumors in our series, we were unable to determine favorable or unfavorable prognostic factors through statistical analysis. Given the lack of pre-GKS T2-weighted or CT images, comparison of symptom development specific to edema and calcification was not possible. Furthermore, since this is a single-institution study, the results are subject to the practice and selection biases of our physicians. For instance, our practitioners have been more inclined to treat a young than an older asymptomatic patient because of the remaining cumulative at-risk years over which the tumor may progress and associated symptoms may occur. The cost/benefit ratio of prophylactic treatment was also not studied.
Despite limitations of the current study, we believe the framework of considering the lesion's natural history and the risk factors for symptom development in the analysis of asymptomatic patients is crucial to determining whether the treatment of such patients is a beneficial, cost-effective option. Given the available published studies and the present analysis, we believe that some patients possess a combination of risk factors that make preemptive treatment appropriate. Additional studies are needed to further define the rates of symptom development for asymptomatic patients treated with GKS and to develop practical clinical guidelines for the practicing neurosurgeon.
Conclusions
Results of our analysis indicated that when patients with asymptomatic meningiomas undergo GKS, the rate of symptom development may decrease compared with previously published rates from natural history studies. Tumor control rate, symptom control, and overall PFS after GKS for patients with asymptomatic meningiomas were quite favorable. Further study is needed to better define the risk/benefit ratio and to provide clinical guidelines for the treatment of asymptomatic meningiomas.
